Join

or

Existing user? Login

Issue : PJ October 2015 online

Sort by: Newest first Oldest first A-Z Z-A

  • Teething baby

    US drug regulator warns against use of homeopathic teething products

    7 OCT 2016 10:44 By Debbie Andalo

    Parents in the United States have been warned to stop giving children homeopathic teething tablets or gels in light of an ongoing inquiry into their safety by the US Food and Drug Administration.

  • Side effects with Bonviva Subscription

    6 NOV 2015 16:21

    Stevens-Johnson syndrome, erythema multiforme and dermatitis bullous have been added as very rare adverse events in the summary of product characteristics for Bonviva (ibandronic acid; Roche). 

  • NICE recommends tolvaptan for polycystic kidney disease Subscription

    6 NOV 2015 16:20

    The National Institute for Health and Care Excellence (NICE) has published final guidance that recommends tolvaptan (Jinarc; Otsuka) for the treatment of autosomal dominant polycystic kidney disease in adults with stage 2 or 3 chronic kidney disease at the start of treatment and with evidence of rapidly progressing disease. The guidance also stipulates that tolvaptan can only be prescribed if the company provides the drug at a pre-agreed discounted rate.

  • Patient and genotype networks showing patients with type 2 diabetes and three subtypes of type 2 diabetes

    Type 2 diabetes found to have three different subtypes Subscription

    5 NOV 2015 15:36
    Comments (1)

    By analysing a large database of patient records, it was found that type 2 diabetics clustered into three groups who tended to experience different complications of the disease.

  • NICE recommends idelalisib for chronic lymphocytic leukaemia Subscription

    5 NOV 2015 14:22

    The National Institute for Health and Care Excellence has published final guidance that recommends idelalisib (Zydelig; Gilead) when used in combination with another cancer treatment rituximab to treat adults with chronic lymphocytic leukaemia who have one of two genetic changes (17p deletion or TP53 mutation) and have not received any other treatment. The guidance stipulates that idelalisib can only be prescribed if the company provides the drug at a pre-agreed discounted rate.

  • NICE does not recommend nab-paclitaxel for pancreatic cancer Subscription

    5 NOV 2015 14:16

    The National Institute for Health and Care Excellence (NICE) has published final guidance that does not recommend nab-paclitaxel (Abraxane; Celgene) for pancreatic cancer, because the cost of using the drug is not justified by its limited benefits compared with current treatments.

  • Controlled drugs consultation Subscription

    5 NOV 2015 10:26

    The National Institute for Health and Care Excellence (NICE) has published a consultation on the safe use and management of controlled drugs. The consultation covers guidance on prescribing, obtaining and supplying, administering, handling, and recording and monitoring use of controlled drugs. It is available ...

  • Briefing for pharmacists delivering MURs for epilepsy patients Subscription

    5 NOV 2015 10:24

    The Pharmaceutical Services Negotiating Committee and the Epilepsy Society have produced a briefing to help pharmacists deliver medicines use reviews (MURs) for patients with epilepsy who are taking antiepileptic drugs. The consultation briefing is available from the Epilepsy Society ...

  • Storage conditions for Ashton & Parsons Subscription

    5 NOV 2015 10:14

    The summary of product characteristics for Ashton & Parsons Infants’ Powders (tincture of matricaria; Alliance) now states that the product should be stored under 25ºC. 

  • NICE recommendations for juvenile idiopathic arthritis Subscription

    5 NOV 2015 10:12

    The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending abatacept (Orencia; Bristol-Myers Squibb), adalimumab (Humira; AbbVie), etanercept (Enbrel; Pfizer) and tocilizumab (RoActemra; Roche) as options for treating juvenile idiopathic arthritis. A consultation on the guidance, which is available from ...

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.